TY - JOUR
T1 - Endorsement of Definitions of Disease Activity States and Improvement Scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10
AU - Machado, Pedro M. M. C.
AU - Landewe, Robert B. M.
AU - van der Heijde, Desiree M.
PY - 2011/7
Y1 - 2011/7
N2 - The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new composite index to assess disease activity in ankylosing spondylitis (AS). Criteria for disease activity states and improvement scores are important for use in clinical practice, observational studies, and clinical trials, and have been proposed by the Assessment of SpondyloArthritis international Society (ASAS). At OMERACT 10, our aim was to obtain endorsement from OMERACT for the ASDAS disease activity states and response criteria proposed by the ASAS membership. This article summarizes the associated discussions, the scientific basis of the validation process, and the results from the voting sessions, and identifies areas for research using the ASDAS. OMERACT participants agreed with the selection of cutoff values, which now have the combined endorsement of ASAS and OMERACT and are ready to be used in clinical practice and in research settings. (J Rheumatol 2011;38:1502-6; doi:10.3899/jrheum.110279)
AB - The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new composite index to assess disease activity in ankylosing spondylitis (AS). Criteria for disease activity states and improvement scores are important for use in clinical practice, observational studies, and clinical trials, and have been proposed by the Assessment of SpondyloArthritis international Society (ASAS). At OMERACT 10, our aim was to obtain endorsement from OMERACT for the ASDAS disease activity states and response criteria proposed by the ASAS membership. This article summarizes the associated discussions, the scientific basis of the validation process, and the results from the voting sessions, and identifies areas for research using the ASDAS. OMERACT participants agreed with the selection of cutoff values, which now have the combined endorsement of ASAS and OMERACT and are ready to be used in clinical practice and in research settings. (J Rheumatol 2011;38:1502-6; doi:10.3899/jrheum.110279)
KW - ANKYLOSING SPONDYLITIS
KW - DISEASE ACTIVITY
KW - RESPONSE CRITERIA
KW - OUTCOME ASSESSMENT
U2 - 10.3899/jrheum.110279
DO - 10.3899/jrheum.110279
M3 - Article
C2 - 21724723
SN - 0315-162X
VL - 38
SP - 1502
EP - 1506
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 7
ER -